Company intelligence / Profile preview

Tetragenex Pharmaceuticals, Inc.

Syosset, New York, United Statespacermonitor.com ↗

Ownership: Private
Employees: ~10
Development stage: Phase 2

Overview

Nemifitide underwent over a dozen clinical trials with evidence of rapid onset antidepressant activity in treatment-resistant patients, generally well tolerated with few side effects. However, the program was discontinued and the company sought licensing partners before ceasing operations.[1][2]

Therapeutic areas: OncologyPsychiatryNeurologyInfectious Diseases
Modalities: Peptides[2]Small molecules (tetracycline derivatives)[2]
Industry: Biotech

Drug pipeline

2 assets

nemifitide

Phase 2

Indications: Major depressive disorder

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Tetragenex Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tetragenex Pharmaceuticals, Inc..

Explore the full profile